Tags

Type your tag names separated by a space and hit enter

Mortality rate and prognostic factors for dogs with severe anaphylaxis: 67 cases (2016-2018).
J Am Vet Med Assoc. 2020 May 15; 256(10):1137-1144.JA

Abstract

OBJECTIVE

To determine mortality rates for dogs with severe anaphylaxis and identify potential prognostic factors.

ANIMALS

67 dogs with suspected anaphylaxis graded as severe.

PROCEDURES

Dogs were classified on the basis of outcome as survivors and nonsurvivors. Medical records were reviewed, and data were extracted including signalment, examination findings, time to hospital admission from onset of clinical signs, CBC results, serum biochemical analysis results, coagulation testing results, and findings on abdominal ultrasonography. Initial treatment within the first 6 hours after hospital admission was recorded for analysis, specifically including the use of epinephrine, diphenhydramine, corticosteroids, antimicrobials, fresh-frozen plasma, and supplemental dextrose.

RESULTS

The overall mortality rate was 14.9% (10/67) for dogs with anaphylaxis graded as severe. Serum phosphorus concentration and prothrombin time (PT) were significantly higher in nonsurvivors, compared with survivors. Nonsurvivors had lower presenting body temperatures than survivors. Serum phosphorus concentration ≥ 12.0 mmol/L, hypoglycemia within 6 hours after hospital admission, high PT value, concurrently high PT and partial thromboplastin time (PTT) values > 50% above the reference range limit, and the need for supplemental dextrose were associated with death. The incidences of coagulopathy and peritoneal effusion were unexpectedly high (85.2% and 65.5% of dogs, respectively) but were not indicative of survival.

CONCLUSIONS AND CLINICAL RELEVANCE

Despite the poor presenting clinical condition seen in dogs with severe anaphylaxis, the rate of survival with treatment was fairly high. Coagulopathy and the presence of peritoneal effusion were common findings in dogs with severe anaphylaxis. Serum phosphorus concentration ≥ 12.0 mmol/L, high PT value, concurrent increases of PT and PTT values > 50% above reference range limits, hypoglycemia within 6 hours after hospital admission, and the need for supplemental dextrose were associated with death.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32364451

Citation

Smith, M Ryan, et al. "Mortality Rate and Prognostic Factors for Dogs With Severe Anaphylaxis: 67 Cases (2016-2018)." Journal of the American Veterinary Medical Association, vol. 256, no. 10, 2020, pp. 1137-1144.
Smith MR, Wurlod VA, Ralph AG, et al. Mortality rate and prognostic factors for dogs with severe anaphylaxis: 67 cases (2016-2018). J Am Vet Med Assoc. 2020;256(10):1137-1144.
Smith, M. R., Wurlod, V. A., Ralph, A. G., Daniels, E. R., & Mitchell, M. (2020). Mortality rate and prognostic factors for dogs with severe anaphylaxis: 67 cases (2016-2018). Journal of the American Veterinary Medical Association, 256(10), 1137-1144. https://doi.org/10.2460/javma.256.10.1137
Smith MR, et al. Mortality Rate and Prognostic Factors for Dogs With Severe Anaphylaxis: 67 Cases (2016-2018). J Am Vet Med Assoc. 2020 May 15;256(10):1137-1144. PubMed PMID: 32364451.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mortality rate and prognostic factors for dogs with severe anaphylaxis: 67 cases (2016-2018). AU - Smith,M Ryan, AU - Wurlod,Virginie A, AU - Ralph,Alan G, AU - Daniels,Erin R, AU - Mitchell,Mark, PY - 2020/5/5/entrez PY - 2020/5/5/pubmed PY - 2020/5/5/medline SP - 1137 EP - 1144 JF - Journal of the American Veterinary Medical Association JO - J. Am. Vet. Med. Assoc. VL - 256 IS - 10 N2 - OBJECTIVE: To determine mortality rates for dogs with severe anaphylaxis and identify potential prognostic factors. ANIMALS: 67 dogs with suspected anaphylaxis graded as severe. PROCEDURES: Dogs were classified on the basis of outcome as survivors and nonsurvivors. Medical records were reviewed, and data were extracted including signalment, examination findings, time to hospital admission from onset of clinical signs, CBC results, serum biochemical analysis results, coagulation testing results, and findings on abdominal ultrasonography. Initial treatment within the first 6 hours after hospital admission was recorded for analysis, specifically including the use of epinephrine, diphenhydramine, corticosteroids, antimicrobials, fresh-frozen plasma, and supplemental dextrose. RESULTS: The overall mortality rate was 14.9% (10/67) for dogs with anaphylaxis graded as severe. Serum phosphorus concentration and prothrombin time (PT) were significantly higher in nonsurvivors, compared with survivors. Nonsurvivors had lower presenting body temperatures than survivors. Serum phosphorus concentration ≥ 12.0 mmol/L, hypoglycemia within 6 hours after hospital admission, high PT value, concurrently high PT and partial thromboplastin time (PTT) values > 50% above the reference range limit, and the need for supplemental dextrose were associated with death. The incidences of coagulopathy and peritoneal effusion were unexpectedly high (85.2% and 65.5% of dogs, respectively) but were not indicative of survival. CONCLUSIONS AND CLINICAL RELEVANCE: Despite the poor presenting clinical condition seen in dogs with severe anaphylaxis, the rate of survival with treatment was fairly high. Coagulopathy and the presence of peritoneal effusion were common findings in dogs with severe anaphylaxis. Serum phosphorus concentration ≥ 12.0 mmol/L, high PT value, concurrent increases of PT and PTT values > 50% above reference range limits, hypoglycemia within 6 hours after hospital admission, and the need for supplemental dextrose were associated with death. SN - 1943-569X UR - https://www.unboundmedicine.com/medline/citation/32364451/Mortality_rate_and_prognostic_factors_for_dogs_with_severe_anaphylaxis:_67_cases_(2016-2018) L2 - https://avmajournals.avma.org/doi/10.2460/javma.256.10.1137?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.